Analyzing Visfatin Levels in Human Milk
Levels of Visfatin/NAMPT in Human Milk.VISFAMILK
Paolo Manzoni · NCT06487286
This study looks at the levels of a substance called Visfatin in breast milk from new mothers to see how it might relate to their babies' health, especially weight loss, during the first month after birth.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Sex | All |
| Sponsor | Paolo Manzoni (other) |
| Locations | 1 site (Ponderano, BI) |
| Trial ID | NCT06487286 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the levels of Visfatin in maternal milk samples collected from mothers during the postpartum period. Milk samples will be taken at three different time points: 48 hours, 7 days, and 30 days after birth, and Visfatin levels will be measured using an ELISA kit. Additionally, maternal plasma/serum will be evaluated to explore correlations between Visfatin levels and various biological and clinical features of both mothers and their newborns. The study focuses on understanding how these levels may relate to newborn clinical conditions, particularly weight loss.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy infants born after 37 weeks' gestation without congenital abnormalities, along with their postpartum mothers.
Not a fit: Patients who may not benefit from this study include those with conditions affecting milk production, such as hypogalactia or agalactia.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of Visfatin as a biomarker for assessing newborn health and weight management.
How similar studies have performed: While the specific focus on Visfatin levels in human milk is novel, similar studies exploring biomarkers in maternal milk have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities * Maternal hospitalization * Acquisition of the informed consent form signed by the patient Exclusion Criteria: * Refusal of the patient to participate in the study * Presence of hypogalactia or agalactia in the patient
Where this trial is running
Ponderano, BI
- Ospedale degli Infermi - ASL BI — Ponderano, BI, Italy (RECRUITING)
Study contacts
- Study coordinator: Paolo Manzoni, Professor
- Email: paolo.manzoni@aslbi.piemonte.it
- Phone: +39 01515156906
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Visfatin Levels in Maternal Milk Samples, Birth Weight, Newborns, Visfatin, Breastfeeding